(Q53258665)

12 May 2018

title

Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. (English)

1 reference

12 May 2018

1 reference

2

1 reference

12 May 2018

author name string

Estefanía Carrasco-García

1

1 reference

12 May 2018

Silvina Grasso

3

1 reference

12 May 2018

Lourdes Rocamora-Reverte

4

1 reference

12 May 2018

Mariano Conde

5

1 reference

12 May 2018

Angeles Gómez-Martínez

6

1 reference

12 May 2018

Pilar García-Morales

7

1 reference

12 May 2018

José A Ferragut

8

1 reference

12 May 2018

Isabel Martínez-Lacaci

9

1 reference

12 May 2018

language of work or name

English

0 references

publication date

1 April 2011

1 reference

12 May 2018

Experimental Cell Research

published in

1 reference

12 May 2018

volume

317

1 reference

12 May 2018

issue

10

1 reference

12 May 2018

page(s)

1476-1489

1 reference

12 May 2018

Changing paradigms--an update on the multidisciplinary management of malignant glioma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

An integrated genomic analysis of human glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Specificity within the EGF family/ErbB receptor family signaling network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Cell signaling by receptor tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Secondary dimerization between members of the epidermal growth factor receptor family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

CDK inhibitors: positive and negative regulators of G1-phase progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Cell cycle. Order from destruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Characterization of a novel epidermal-growth-factor-receptor-related 200-kDa tyrosine kinase in tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

EGF mutant receptor vIII as a molecular target in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

The EGFRvIII variant in glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Epidermal‐Growth‐Factor‐Dependent Activation of the Src‐Family Kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Epidermal growth factor receptor targeting in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Evolutionary analysis of the ErbB receptor and ligand families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

The EGF receptor family: spearheading a merger of signaling and therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

c-erbB-4/HER4: friend or foe?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Nuclear EGFR contributes to acquired resistance to cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Designer therapies for glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

10.1016/J.YEXCR.2011.03.015

7 January 2021

Identifiers

DOI

1 reference

12 May 2018

PubMed ID

21439954

1 reference

12 May 2018